Blocking the RAAS, particularly with olmesartan, lowers blood pressure, increases renal blood flow and decreases the occurrence of kidney damage.
These benefits of RAAS blockade are accompanied by a fall in kidney capacity. This can involve:
* lowered GFR,
* decreased sodium retention,
* increased potassium retention,
* decreased acid excretion,
* decreased phosphate excretion and
* lowered stimulus to RBC production.
Out of range values observed with RAAS blockade can include:
* high creatinine,
* high urea,
* low sodium,
* high potassium,
* acidosis (low CO2 or bicarbonate),
* low calcium,
* high phosphate and
* anemia.
The out of range electrolytes (sodium, potassium, CO2 or bicarbonate, calcium and phosphate) could be of immediate concern. But they can be simply modulated by:
* limitation of potassium rich foods
* increased intake of salt (sodium chloride)
* daily dosage with sodium bicarbonate
* dosage with calcium carbonate (or calcium acetate) with high phosphate meals as required.